Related Experiment Videos

Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention?

Huseyin Bozbas1, Aylin Yildirir, Serdar Mermer

  • 1Department of Cardiology, Faculty of Medicine, Baskent University, Ankara, Turkey. hbozbas@gmail.com

Advances in Therapy
|July 31, 2007
PubMed

Insights

Low-dose pravastatin did not prevent cardiac enzyme elevation after percutaneous coronary intervention (PCI). This study found no significant difference in serum creatine kinase-myocardial band (CK-MB) or cardiac troponin I (cTpI) levels between pravastatin groups and controls post-PCI.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Percutaneous coronary intervention (PCI) can lead to serum cardiac enzyme elevation, a predictor of long-term outcomes.
  • Statins are hypothesized to mitigate PCI-related cardiac enzyme elevations.

Purpose of the Study:

  • To evaluate the short-term efficacy of low-dose pravastatin in reducing serum creatine kinase-myocardial band (CK-MB) and cardiac troponin I (cTpI) levels after elective PCI.

Main Methods:

  • A randomized controlled trial involving 93 patients undergoing elective PCI.
  • Patients were assigned to receive either 10 mg/d pravastatin, 40 mg/d pravastatin, or no lipid-lowering medication (control).
  • Serum CK-MB and cTpI levels were measured pre-PCI and at 6, 24, and 36 hours post-PCI.

Main Results:

  • All patients exhibited significant increases in serum CK-MB and cTpI levels post-PCI.
  • No statistically significant reduction in postprocedural CK-MB or cTpI levels was observed in patients receiving pravastatin compared to the control group.
  • Demographics and PCI procedural characteristics were similar across all groups.

Conclusions:

  • Preprocedural pravastatin therapy at 10 mg/d and 40 mg/d appears insufficient to prevent short-term cardiac enzyme elevation following PCI.
  • Further research is warranted to explore optimal statin regimens for mitigating PCI-induced myocardial injury.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...